Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Other Non-Current Liabilities (2022 - 2025)

Historic Other Non-Current Liabilities for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $500000.0.

  • Zentalis Pharmaceuticals' Other Non-Current Liabilities fell 4979.92% to $500000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $500000.0, marking a year-over-year decrease of 4979.92%. This contributed to the annual value of $849000.0 for FY2024, which is 5230.34% down from last year.
  • Zentalis Pharmaceuticals' Other Non-Current Liabilities amounted to $500000.0 in Q3 2025, which was down 4979.92% from $500000.0 recorded in Q2 2025.
  • Zentalis Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $45.0 million for Q1 2022, and its period low was $500000.0 during Q2 2025.
  • Moreover, its 4-year median value for Other Non-Current Liabilities was $1.3 million (2024), whereas its average is $4.7 million.
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' Other Non-Current Liabilities tumbled by 9601.58% in 2023, and later crashed by 2779.02% in 2024.
  • Zentalis Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $2.6 million in 2022, then crashed by 32.06% to $1.8 million in 2023, then crashed by 52.3% to $849000.0 in 2024, then tumbled by 41.11% to $500000.0 in 2025.
  • Its Other Non-Current Liabilities was $500000.0 in Q3 2025, compared to $500000.0 in Q2 2025 and $558000.0 in Q1 2025.